News - Events

This meeting will focus on issues relating to parallel trade, which is the cross-border sale of pharmaceuticals within the EU by traders outside of the manufacturer’s distribution system without the manufacturer’s consent. Parallel trade is a form of arbitrage which has been upheld by the European Court of Justice as being consistent with the principles of free trade. This meeting will take a look at parallel trade in the context of Brexit and other contemporary legal issues.

This event will focus on the latest research and development in delivery systems for medicines that aim to address difficult targets within the human body. For the first time in this series, delegates will learn about oligonucleotide delivery during an opening 'focus day.' The main conference will focus on current developments in messenger RNA therapeutics as immunotherapies and vaccines.

This conference will explore the use of three-dimensional (3D) cell culture for drug screening and projects involving cell therapy. A 3D cell culture is an artificial environment in which biological cells are allowed to grow and interact with their surroundings in all three dimensions. The discussion will also include advances in organs-on-chips which are three-dimensional microfluidic cell culture chips that mimic the physiological response of entire organs to disease. The chips are a tool for modelling disease and identifying targets for new therapies.

In the past decade, many scientific breakthroughs have been achieved in the treatment of cancer through basic research. This meeting will discuss that latest paradigm shift: personalised immunotherapies in combination with other drugs for the treatment of cancer. This shift is taking place against a backdrop of the development and regulatory approval of new monoclonal antibodies, cancer vaccines, adoptive cell therapies and immune-checkpoint therapies. 

This meeting will explore the latest applications of artificial intelligence to drug discovery including the use of AI for lead compound screening, multi-parameter optimisation, disease modelling, drug synthesis and design.

Antimicrobial resistance (AMR) describes the ability of a microorganism like bacteria, viruses and some parasites to stop an antibiotic, antiviral drug or antimalarial drug from working. As a result, standard treatments for many serious diseases become ineffective, the infections persist and an increasing number of people are harmed. A subset of AMR is antibacterial resistance.

This meeting will look at different aspects of developing and delivering pre-filled syringes such as on-body injectors and container closure interaction. Delegates will learn about the changing global marketplace and challenges facing the industry.

BioTrinity is a long-running two-day life sciences conference that will take place in 2020 in central London from 28-29 April. The conference focuses on partnering, investment and collaboration, and aims to inspire growth and create opportunities for all who attend. The core delegate mix includes early-stage and emerging biotech, medtech and digital health companies, big pharma executives and life sciences investors.

The pharmaceutical microbiology industry has seen many changes in recent years. These changes include the discovery of new methods for multiplying microbial organisms, enhanced knowledge of the human microbiome, and new regulation. This meeting will bring together experts from industry to discuss data integrity as it affects microbiology methods, environmental monitoring and automated endotoxin testing and process automation.

This meeting will review the current state of pain treatment including issues around opioid-based treatments. Discussions will focus on drug development from the preclinical to clinical stage and candidate treatments in the pipelines of leading pharmaceutical companies. There will also be a review of non-opioid targets for pain medications including the cannabinoid receptor 2 and other targets. The therapeutic efficacy of neurotoxins will also be addressed, including novel botulinum-based constructs.